Current location: slot game xbox > hit it rich casino slots game > www777 casino > main body

www777 casino

2025-01-13 2025 European Cup www777 casino News
Dimopoulos shines in double OT and Northern Illinois beats Fresno State 28-20 in Idaho Potato Bowlwww777 casino

newcleo's LFR (Lead-cooled Fast Reactor)-AS-200 technology fully embodies the circular economy model using mixed oxide (MOX) as fuel (i.e. reprocessed nuclear wastes), in line with NEXTCHEM's vision on circularity. The JVC will facilitate and accelerate the development and commercialization of the "LFR-AS-200", thanks to the synergic competences of the two shareholders in the energy industry. Upon execution of binding agreements, new cleo will take a 40% stake in the NEXTCHEM's newly incorporated company focused on creating new intellectual property (IP) and performing technical services. The deal will result in NEXTCHEM being granted newly issued shares up to 5% of new cleo's share capital at pre-money valuation, subject to the achievement of certain milestones the first of which is new cleo's entrance into the JVC, and the last being linked to the final investment decision (FID) by the first client. NEXTCHEM will contribute to the JV skills, management and engineering competences and tools, as well as a dedicated commercial platform for the deployment of LFR-AS-200 projects, to complement new cleo's ever growing expertise in the nuclear field. The JVC will benefit from competences of both parties and create its own new IP. In particular, new cleo will develop the nuclear reactor for its own LFR-AS-200 technology, while NEXTCHEM will leverage its own distinctive know-how to enable the JVC to deliver the extended basic design, procure the critical proprietary equipment relevant to the Conventional Island and Balance of Plant of the nuclear power plant, and provide project management/integration services to new cleo. The Conventional Island and the Balance of Plant are essential to convert nuclear energy into electrical power dispatchable to the grid or used to serve chemical districts according to NEXTCHEM's e-Factory format, thus contributing to the decarbonization of the chemical industry by producing low-carbon chemicals and e-fuels. The JVC will also provide integration services to other SMR (Small Modular Reactor) and AMR technology providers who are not competing with new cleo. This business model will serve the industrialization of the energy transition for any customer potentially interested in implementing power plants based on Generation IV nuclear technologies. TECNIMONT (Integrated E&C Solutions) will be granted a preferred partner status for the delivery of projects, thanks to its state-of-the-art modularization approach to optimize construction and planning methodology, reducing time and costs. The transaction is expected to be finalized by the end of February 2025. Alessandro Bernini , CEO of MAIRE , commented: "This collaboration is a clear representation of our ability to offer a complete range of services for energy transition combining our innovative vision on sustainable technology solutions with our traditional competences in integrated engineering solutions. Today we set a further milestone in our progressive path to implement carbon-neutral chemistry models based on safe, reliable and competitive energy supply."

The Latest: Former President Jimmy Carter is Dead at age 100

Jimmy Carter: Many evolutions for a centenarian ‘citizen of the world’

Abortions up slightly in United States

Fine Gael won 35 seats in the 2020 election, but 18 of those TDs did not seek re-election in Friday’s poll. An exit poll puts the party’s support at 21%, a fraction of a percentage behind the main opposition party Sinn Fein. Mr Harris, the outgoing Taoiseach, was elected with 16,869 first preference votes, well above the quota. He celebrated with his wife Caoimhe, his parents Bart and Mary, his sister Gemma and his political team at the count centre in Greystones, Co Wicklow. Ahead of his re-election, Mr Harris told reporters he was “cautiously optimistic” about the election result and said it was “clear that my party will gain seats”. “It’s also clear that Fine Gael will top the poll in at least 10 constituencies, many more than we did the last time, that we will gain seats in constituencies where we haven’t had seats in many years, like Tipperary South and Waterford, and that we will add second seats in other constituencies as well,” he said. “I think the people of Ireland have now spoken. We now have to work out exactly what they have said, and that is going to take a little bit of time.” In one of the five consecutive broadcast media rounds he did from the Greystones count centre, he said there were a lot of areas where there were “straight shoot-outs” between Fianna Fail and Fine Gael for final seats. He described the Sinn Fein vote as “pretty significantly down”, the Fianna Fail vote as “marginally down” and the Fine Gael vote as “static” compared with its 2020 vote. He said it was “a very close, a very competitive election” and that “we haven’t seen a Sinn Fein surge or anything like it”. He said: “It was predicted by many that I would become the Taoiseach for a brief period of time, take over from Leo Varadkar, and then have to rebuild my party from the opposition benches as Sinn Fein led a government. “We don’t know what’s going to happen on government formation yet, but that is now looking less likely than it was.” He acknowledged that it was “a very difficult day” for the Green Party and paid tribute to their work in the coalition government, alongside his party and Fianna Fail. “Definitely, politics in Ireland has gotten much more fragmented,” he said. Fine Gael minister Helen McEntee said that her party’s campaign had been “positive”. “The feeling on the doors was very much that people were relatively happy with the government,” she said on RTE Radio. “It will come down to the last seats and it will come down to transfers,” she said of the final result, adding that Fianna Fail and Fine Gael were performing better than the exit poll estimated.SAN DIEGO , Dec. 5, 2024 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Five9, Inc. (NASDAQ: FIVN ) securities, including call options, between June 4, 2024 and August 8, 2024 . Five9 provides software for a cloud-based contact center. For more information, submit a form , email attorney Aaron Dumas, Jr. , or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Five9, Inc. (FIVN) Misled Investors Regarding its Sales Execution and Efficiency Issues According to the complaint, during the class period, defendants failed to disclose that: (i) Five9's net new business was not "strong irrespective of the macro" and was, in fact, hampered by macroeconomic issues such as constrained and scrutinized customer budgets; (ii) Five9 was in the midst of a challenging bookings quarter due, in part, to sales execution and efficiency issues, and the Company was not "seeing very strong bookings momentum"; and (iii) Defendants did not have "enough information in terms of [their] existing customers that are going live" such that the statements that Five9 would see a positive inflection in its dollar-based retention rate lacked a reasonable basis. Plaintiff alleges that on August 8, 2024 , Five9 released its second quarter 2024 financial results in which the Company reduced its annual revenue guidance due to "recent bookings trends and the uncertain economic conditions." During the earnings call held that same day, the Company revealed it "had a challenging bookings quarter" due to "constrained and scrutinized" customer budgets and sales execution issues. Defendants announced remedial changes to address Five9's sales execution and efficiency issues. It was further revealed that "Q2 new logo bookings came in softer than expected" and that the Company was "no longer assuming" a dollar-based retention rate inflection in the second half of the year because of a "more muted seasonality in our service bookings[.]" On this news, Five9's common stock price dropped over 26%, from $42.47 per share on August 8, 2024 to $31.22 per share on August 9, 2024 . What Now : You may be eligible to participate in the class action against Five9, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by February 3, 2025 . A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP : Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Five9, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP

Advisors Asset Management Inc. increased its holdings in shares of Western Digital Co. ( NASDAQ:WDC – Free Report ) by 32.0% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,418 shares of the data storage provider’s stock after buying an additional 344 shares during the period. Advisors Asset Management Inc.’s holdings in Western Digital were worth $97,000 as of its most recent filing with the Securities & Exchange Commission. Other large investors have also recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Western Digital by 6.8% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 4,401 shares of the data storage provider’s stock worth $300,000 after purchasing an additional 280 shares during the last quarter. Tidal Investments LLC boosted its holdings in shares of Western Digital by 25.4% during the first quarter. Tidal Investments LLC now owns 4,916 shares of the data storage provider’s stock valued at $335,000 after acquiring an additional 997 shares during the period. Swedbank AB bought a new position in shares of Western Digital during the first quarter worth about $8,492,000. DekaBank Deutsche Girozentrale increased its holdings in shares of Western Digital by 338.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 234,605 shares of the data storage provider’s stock worth $15,654,000 after acquiring an additional 181,141 shares during the period. Finally, Bright Futures Wealth Management LLC. acquired a new stake in shares of Western Digital in the 1st quarter worth about $262,000. Institutional investors own 92.51% of the company’s stock. Western Digital Price Performance NASDAQ WDC opened at $72.99 on Friday. Western Digital Co. has a 1 year low of $46.47 and a 1 year high of $81.55. The business’s fifty day moving average is $66.98 and its two-hundred day moving average is $69.11. The stock has a market capitalization of $25.23 billion, a P/E ratio of 43.08 and a beta of 1.40. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.91 and a current ratio of 1.47. Insiders Place Their Bets In other news, SVP Gene M. Zamiska sold 2,169 shares of Western Digital stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $61.96, for a total transaction of $134,391.24. Following the transaction, the senior vice president now owns 32,601 shares in the company, valued at approximately $2,019,957.96. The trade was a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website . Also, CEO David Goeckeler sold 75,000 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $70.32, for a total value of $5,274,000.00. Following the transaction, the chief executive officer now directly owns 896,630 shares in the company, valued at $63,051,021.60. The trade was a 7.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last quarter, insiders have sold 185,963 shares of company stock worth $13,154,039. Company insiders own 0.30% of the company’s stock. Wall Street Analyst Weigh In WDC has been the subject of several recent analyst reports. BNP Paribas decreased their target price on shares of Western Digital from $95.00 to $90.00 in a research report on Thursday, October 24th. Barclays increased their price objective on Western Digital from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Morgan Stanley lifted their target price on Western Digital from $94.00 to $100.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. UBS Group reduced their price target on Western Digital from $74.00 to $72.00 and set a “neutral” rating for the company in a research report on Thursday, October 24th. Finally, Rosenblatt Securities reissued a “buy” rating and set a $115.00 price target on shares of Western Digital in a report on Friday, October 25th. Six equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Western Digital presently has a consensus rating of “Moderate Buy” and an average target price of $87.71. Get Our Latest Stock Report on WDC Western Digital Company Profile ( Free Report ) Western Digital Corporation develops, manufactures, and sells data storage devices and solutions in the United States, China, Hong Kong, Europe, the Middle East, Africa, rest of Asia, and internationally. It offers client devices, including hard disk drives (HDDs) and solid state drives (SSDs) for desktop and notebook personal computers (PCs), gaming consoles, and set top boxes; and flash-based embedded storage products for mobile phones, tablets, notebook PCs, and other portable and wearable devices, as well as automotive, Internet of Things, industrial, and connected home applications. Read More Want to see what other hedge funds are holding WDC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Western Digital Co. ( NASDAQ:WDC – Free Report ). Receive News & Ratings for Western Digital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Western Digital and related companies with MarketBeat.com's FREE daily email newsletter .Cole Anthony hit the game-winning basket with 1.3 seconds left to cap a furious rally as the host Orlando Magic erased a 21-point deficit and completed a season sweep of the Brooklyn Nets with a 102-101 victory on Sunday. The Magic ended their fourth win over the Nets this season on a 22-4 run over the final 7:16 and capped the comeback on Anthony's dramatic shot. After Jalen Wilson sank two free throws with 6.2 seconds left, Orlando called its final timeout. Rookie Tristan da Silva inbounded to Anthony from the left sideline and the guard moved to the basket. Anthony got by Keon Johnson and Simmons and hit an uncontested stepback four-foot jumper. After Anthony's clutch shot, Da Silva blanketed Cam Thomas at the left corner as the Brooklyn guard missed a 3-point try at the horn. Da Silva led the Magic with 21 points to go along with seven assists and six rebounds. Goga Bitadze collected 11 rebounds and added 19 points, including a free throw that gave Orlando its first lead since the opening quarter with 17.7 seconds left. Caleb Houstan hit two 3s in the comeback and added 12 while fellow reserve Anthony contributed 10. Anthony did not play in the first half but replaced Jalen Suggs, who exited at halftime with a sprained wrist. Thomas returned from a hamstring injury and led all scorers with 25 off the bench but the Nets did not make a field goal in the final 7:16 and lost for the 10th time in 13 games. Wilson added 16 and Keon Johnson contributed 14 as the Nets also lost Cameron Johnson to a sore left hip after the third. The Nets took the loss after trading Dorian Finney-Smith and Shake Milton to the Los Angeles Lakers for D'Angelo Russell and Maxwell Lewis. After taking a 61-43 lead by halftime, the Nets held a 71-50 lead when Keon Johnson hit three free throws with 7:55 left in the third. Thomas scored Brooklyn's final six points of the third to give the Nets an 83-68 lead into the fourth and Wilson sank three triples in a span of 47 seconds to up the lead to 97-80 before Orlando stormed back. --Field Level Media/Reuters( MENAFN - PR Newswire) Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI ) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. (HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million, cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million, before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon, PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen, CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." "HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China," said Dr. Robert Y. Zhao, President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million, Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan, has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024. Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024. Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein, MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20th at 8:00 AM EST (5:00 AM PST) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio. To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at , as well as on the Investor and News section of Aadi's website at . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024, and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: [email protected] SOURCE Aadi Bioscience MENAFN19122024003732001241ID1109014329 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

As 2024 fades away and 2025 looms on the horizon, it is natural for both employees and employers to reflect on the past year while contemplating what lies ahead. Both groups are undoubtedly hoping for an improvement in global economic activity and better economic prospects within their respective regions. From the employer’s perspective, increased business activity translates to greater profitability. Meanwhile, workers remain optimistic that enhanced revenue generation and profits will lead to better wages, salaries, and benefits. Historically, workers have borne the brunt of economic downturns, facing inadequate pay, high taxation—whether direct or indirect—job insecurity, and poor-quality, unsustainable employment. In 2024, some reports suggested that unemployment was trending downward. However, with layoffs and retrenchments still affecting workers, the accuracy of such claims is questionable. In a global economy increasingly driven by technology and artificial intelligence, there is a growing risk of further job losses as physical labour is replaced. The pressures on social security systems are intensifying as workforce numbers dwindle due to retrenchment, retirement, and attrition. This issue becomes even more acute when one considers the thousands of school leavers entering the job market each year, many of whom find themselves unable to secure gainful employment or access higher education and vocational training opportunities. Promoting entrepreneurship as a solution to unemployment requires more than lip service. A sustainable entrepreneurship strategy must be supported by dedicated funding, market access, and resources to help businesses thrive. Vendors and entrepreneurs must embrace innovation in their offerings to attract and retain clientele. It makes sense to focus on ventures with realistic growth potential and long-term viability. Aligning new employment initiatives with national priorities is critical, and food security offers an ideal starting point. You Might Be Interested In Crystal Beckles-Holder, 2nd runner up in regional competition GUYANA: Body of child found after gold mine collapses Barbadians asked to help with return tickets for Haitians Incentives to encourage involvement in agro-industrial projects can drive both job creation and economic sustainability. Countries must also explore their unique strengths. For example, Barbados, famed for its sun, sea, and hospitality, could position itself as a global leader in rehabilitation healthcare, creating opportunities for nurses, medical professionals, support staff, and other associated services. To remain competitive, countries must look inward and leverage their distinct advantages rather than solely attempting to rival other jurisdictions. Furthermore, foreign borrowing should always serve productive and provident purposes, ensuring long-term benefits for the nation. Dennis De Peiza is a Labour & Employee Relations Consultant with Regional Management Services Inc.UCD: Your smart TV is watching what you watchDallas plays Winnipeg after Marchment's 2-goal performance

Abortions up slightly in United StatesFormer US President Jimmy Carter dies at 100AENT Stock Soars to 52-Week High, Hits $4.99 Amidst 393% Annual Surge

Share Tweet Share Share Email Electrical Solutions, the official representative of EKF in Russia, has been honored with the Breakthrough Brand title in the 2024 Brand of the Year awards. This demonstrates a mission to adapt to market needs and deliver practical solutions. The Brand of the Year awards acknowledge businesses that influence their industries through constant development, and the company stands out for its contributions to advancing electrical solutions. This milestone for Electrical Solutions comes alongside other achievements, including the expansion of its product range and the implementation of sustainability initiatives. Representing the global brand EKF, Electrical Solutions has worked to meet the increasing demands of a growing market while exploring new technologies. Innovation with a Practical Focus Electrical Solutions has focused on providing useful and reliable products. Over the past few years, the company has rolled out several new technologies aimed at simplifying processes for businesses and professionals. For instance, the launch of the TERACOM line of telecommunications equipment in 2023 introduced tools designed to integrate seamlessly with modern industrial systems. In 2024, the company expanded its telecommunications offerings to include active equipment, reflecting a focus on staying ahead of market demands. Another notable development is the EKF Connect Industry platform, which enables businesses to monitor production processes and energy consumption in real time. Tools like this have made it easier for users to manage resources effectively. The Marketing Director for the company commented, “This recognition is a result of our efforts to address real-world challenges with solutions that align with market needs. It’s encouraging to see these initiatives acknowledged at this level.” Electrical Solutions: Progress Beyond Product Innovation This recent recognition extends beyond product development. Sustainability has also been a key focus. One innovative program, launched in 2022, introduced measures to reduce waste and improve energy efficiency while ensuring safe and fair working conditions. These efforts earned them a spot in the ESG index, where it was rated “second level” for meeting high standards in environmental, social, and governance (ESG) practices. The program also supports employee development and community engagement. This broader focus helps balance the company’s goals for business growth with responsible practices that benefit stakeholders. The emphasis on ESG principles aligns with EKF’s broader vision of being a sustainable and forward-thinking brand. Scaling for the Future As a Brand Representative of EKF In addition to continuing with its ongoing initiatives, Electrical Solutions is looking to make major expansions to support its growth. The company is planning to become a joint stock company and will have an initial public offering (IPO) in 2025–2027. The move is expected to draw investments there to fund higher capacity production and new projects. The company has already grown its product range to 427 items, including modular equipment, sockets, and telecommunications solutions. With plans to further expand its facilities and add advanced manufacturing technologies, they aim to meet the growing demand for electrical solutions. Localizing production has been another priority, helping the company streamline logistics and maintain quality standards. A Recognition of Efforts Winning the Brand of the Year award highlights efforts to address challenges in the electrical solutions market. Rather than relying on flashy campaigns, the company has focused on practical improvements and meaningful contributions. The award is a reflection of its ability to grow while remaining responsive to the needs of professionals and businesses alike. That recognition also highlights the need for innovation to achieve the same. Electrical Solutions has been working closely with the brand as the official representative of EKF to bring innovative solutions to the market. The key to success has been sustainability initiatives, product development, and working with industry professionals. Growth and Responsibility Balance As it looks ahead, Electrical Solutions is balancing growth with responsibility. The IPO will help the company expand its operations, but the company will continue to maintain high standards in quality and sustainability. It is localizing production to create a more efficient and reliable supply chain that is beneficial to partners and end users. A central role in the company’s plans is also the company’s focus on sustainability. ESG FAST TRACK is an example of how businesses can put environmental and social goals on the same level as financial goals. A balanced approach ensures that Electrical Solutions and EKF will be able to continue to produce meaningful contributions to the Russian electrical equipment market. Moving Forward While winning Brand of the Year is a great milestone, it’s only one part of the larger story for Electrical Solutions. It’s clear that the company is doing the right things to adjust to changing industry needs and establish a base for long-term growth. The approach it took, which was based on working on practical tools, expanding its capabilities, and human sustainability principles, is thoughtful. The company Electrical Solutions has plans for further expansion, new product launches, and will continue to represent EKF to be an important brand in the electrical solutions industry in Russia. From here forward, we expect the needs of the company’s partners and customers to remain its priority so that growth also serves the interests of all stakeholders. Related Items: Electrical , Industry Share Tweet Share Share Email Recommended for you Top 5 Platforms for Tracking Climate Technologies and Industry News Exploring the Future of Metals | Innovations and Trends in the Industry Augmented Reality in Civil Engineering: Revolutionizing the Industry Comments

European Cup News

European Cup video analysis

  • new casino slots 2024
  • fortune v
  • jiliasia withdrawal
  • jili jili
  • fish gambling app
  • jiliasia withdrawal